Loading
LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).
LNS8801 is an investigational agent whose form is not stated in the registry developed by Linnaeus Therapeutics. Its target is Estrogen receptor (ERα). ClinicalTrials.gov describes the intervention as: G protein-coupled estrogen receptor (GPER) agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06624644 (A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma), in melanoma. The largest, NCT06624644, plans to enrol 135 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
PubChem lists LNS8801 as a synonym of this record, which is drawn without the enantiomer assignment.
Investigational agent whose form is not stated in the registry directed at Estrogen receptor (ERα), as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Estrogen receptor (ERα).
1.LNS8801 slips into a pocket on Estrogen receptor (ERα).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LNS8801" OR ABSTRACT:"LNS8801") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LNS8801, not a curated reading list.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.